

AMENDMENT TO THE CLAIMS

Please amend Claims 1 and 12, and cancel Claims 19, 20, 23, 26-28, and 36-38 as shown in the following listing of the claims:

1. (Currently amended) A method for determining whether a human immunodeficiency virus type 1 (HIV-1) has an increased likelihood of having a reduced susceptibility to treatment with amprenavir, comprising: detecting whether the protease encoded by said HIV-1 exhibits the presence ~~or absence~~ of a mutation associated with reduced susceptibility to treatment with said protease inhibitor at amino acid position 11, ~~32~~, 34, ~~43, 46~~, 47, 48, 50, ~~54, 71~~, 76, ~~82~~, 83, ~~84~~, 91 or 95 of an amino acid sequence of said protease, wherein the mutation at amino acid position 34 is Q, the mutation at amino acid position 43 is T, and wherein the presence of said mutation indicates that the HIV-1 has an increased likelihood of having reduced susceptibility to treatment with amprenavir, with the proviso that said mutation is not V32I, ~~M46I, M46L~~, I47V, or I50V, I54L, I54M, I54V, I54T, V82A, V82F or I84V, and wherein the level of susceptibility, mutations, and position number are compare to the protease sequence of the NL4-3 reference strain.
- 2.-11. (Canceled)
12. (Currently amended) The method of claim 1, wherein the amino acid at position 11, 48, ~~54, 71~~, 76, ~~82~~, ~~84~~, 91 or 95 of said protease is an amino acid having a neutral, hydrophobic or non-polar side chain.
13. (Original) The method of claim 12, wherein the amino acid at position 11 of said protease is I or L.
- 14.-17. (Canceled)
18. (Original) The method of claim 12, wherein the amino acid at position 48 of said protease is M.
- 19.-20. (Canceled)
21. (Original) The method of claim 12, wherein the amino acid at position 76 of said protease is V.

22.-23. (Canceled)

24. (Original) The method of claim 12, wherein the amino acid at position 91 of said protease is A or V.

25. (Original) The method of claim 12, wherein the amino acid at position 95 of said protease is F.

26.-28. (Canceled)

29. (Previously presented) The method of claim 1, wherein the amino acid at position 83 of said protease is an amino acid with an acidic, hydrophilic or polar side chain.

30. (Canceled).

31. (Original) The method of claim 1, wherein the amino acid at position 83 of said protease is D.

32.-38. (Canceled).

39. (Original) The method of claim 1, wherein the amino acid at position 91 of said protease is an amino acid with a neutral, hydrophobic, non-polar, hydrophilic or polar side chain.

40. (Original) The method of claim 1, wherein the amino acid at position 91 of said protease is an amino acid with a neutral, hydrophilic or polar side chain.

41. (Original) The method of claim 40, wherein the amino acid at position 91 of said protease is S.

42. (Original) The method of claim 1, wherein the method comprises detecting the presence or absence of a mutation associated with reduced susceptibility to treatment with said protease inhibitor at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 of the amino acid positions.